Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer
Vaxiion Therapeutics, a clinical stage biotech company based in California, has initiated a phase 1 clinical trial of its recombinant bacterial minicell-based oncolytic immunotherapy VAX014 ... Read More
SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer
In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with Hong Kong-based Lee's Pharmaceutical, has announced the ... Read More
Merck to acquire Australian biotech firm Viralytics for $394m to bolster oncolytic immunotherapy treatments
Significant Acquisition in Pharma Industry: US pharmaceutical giant Merck has announced a definitive agreement to acquire Viralytics, an Australian biotech company, for AUD 502 million ... Read More